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Abstract
Background: Anthrax is caused by Bacillus anthracis that produce two exotoxins, lethal toxin and
edema toxin. The lethal toxin is composed of the lethal factor (LF) complexed with the cell binding
protective antigen (PA83, 83 kDa). Likewise, the edema factor (EF) binds to the PA83 to form the
edema toxin. Once PA83 is bound to the host cell surface, a furin-like protease cleaves the full-
length, inactive protein into 63 kDa and 20 kDa antigens (PA63 and PA20). PA63 forms a heptamer
and is internalized via receptor mediated endocytosis forming a protease-stable pore, which allows
EF and LF to enter the cell and exert their toxic effects.
Both proteolytically cleaved protective antigens (PA63 and PA20 fragments) are found in the blood
of infected animals. The 63 kDa protective antigen PA63 fragment has been thoroughly studied while
little is known about the PA20.
Methods: In this study we examined the role of PA20 using high throughput gene expression
analysis of human peripheral blood mononuclear cells (PBMC) exposed to the PA20. We
constructed a PA mutant in which a Factor Xa proteolytic recognition site was genetically
engineered into the protective antigen PA83  to obtain PA20  using limited digestion of this
recombinant PA83 with trypsin.
Results:  Global gene expression response studies indicated modulation of various immune
functions and showed gene patterns indicative of apoptosis via the Fas pathway in a subset of the
lymphoid cells. This finding was extended to include observations of increased Caspase-3 enzymatic
activity and the identification of increases in the population of apoptotic, but not necrotic cells,
based on differential staining methods. We identified a list of ~40 inflammatory mediators and heat-
shock proteins that were altered similarly upon exposure of PBMC to either rPA20 or B. anthracis
spores/vegetative cells.
Conclusion: This study shows that the PA20 has an effect on human peripheral blood leukocytes
and can induce apoptosis in the absence of other PA components.
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Background
Bacillus anthracis, the etiologic agent of anthrax, possesses
three primary, plasmid-encoded, virulence factors: lethal
and edema Toxins encoded by the pXO1 plasmid [1,2]
and a poly-γ-D-glutamic acid capsule, encoded by the
pXO2 plasmid [1]. Lethal toxin is composed of lethal fac-
tor (LF, 90.5 kDa) [3], a Zn+2 dependent metalloprotease
which cleaves several members of the mitogen activated
protein kinase kinase (MAPKK) family [4-7] and, in com-
plex with protective antigen (PA, 63 kDa referred to as
PA63), is responsible for the lethal action of anthrax toxin.
Similarly, edema toxin is composed of PA63 in combina-
tion with edema factor (EF, 88.8 kDa), a calmodulin-
dependent adenylate cyclase that elevates host target cell
intracellular cyclic AMP levels causing deregulation of cel-
lular physiology and edema [8]. Protective antigen is
secreted by the organism as an 82.7-kDa protein referred
to as PA83 [9] and only binds LF or EF when activated by
protease cleavage to form PA63 [10]. In a model based on
studies in cell culture, PA83 binds to ubiquitous host cell
membrane receptors [11] and is cleaved by a cell-associ-
ated furin type protease [12,13] to form PA63, which then
oligomerizes with other PA63 molecules to form an hep-
tamer. The heptamer forms a prepore structure to which
LF or EF bind to form lethal toxin or edema toxin, respec-
tively [10]. It has generally been assumed that the 20 kDa
remainder of the PA83 molecule following cleavage serves
no function. Once formed, the complex is translocated
into the target host cell where LF and EF exert their toxic
effects [14,15]. In contrast to this widely held cell culture
model, no PA83 has been demonstrated in the peripheral
blood of infected animals, but only PA63 complexed with
LF, and possibly EF, was found thereby supporting the
model that the PA63/LF complex is pre-formed before
binding to the target cell [16,17]. Serum protease activity
has been reported that rapidly cleaves PA83 to form PA63
and rPA20. This activity is heat labile at 56°C, requires cal-
cium, and occurs in a broad variety of animals, including
primates, horses, bovines, guinea pigs, rabbits, and chick-
ens [16,17]. Our objective was to determine if rPA20 has
activity on human peripheral blood leukocytes and
obtain information as to which type of leukocytes was
being affected.
Note: Studies were conducted initially with the commer-
cially prepared 20 kDa fragment of PA, from LIST Biolog-
ical Laboratories, Inc., which required purification to
remove minor amounts of contaminating PA63. It is
important to preface this report by stating that after a few
studies were conducted with the purified PA63 free mate-
rial it was determined that the commercially obtained
product was actually 17 kDa rather than 20 kDa. There-
fore, we prepared a recombinant (r) PA20 that lacked the
trypsin cleavage site that would produce PA17. Upon
trypsin cleavage, the resultant rPA20 was purified and used
in all subsequent studies. However, similar data were
obtained using the List preparation PA17 and in-house
rPA20 for the global microarray studies. All subsequent
studies were carried out using only rPA20.
Note: microarray data have been submitted to the Gene
Expression Omnibus (GEO) and can be searched using
the Platform ID: GPL3033, Series:GSE12533.
Methods
Removal of PA63 from PA17 by immunoaffinity
Commercially obtained 20 kDa fragment of PA, (LIST
Biological Laboratories, Inc, Campbell, CA) is now
referred to as PA17. It contained trace amounts of PA63 and
removal of this contamination was achieved by immu-
noaffinity chromatography. In this procedure the mono-
clonal antibody BA-PA2II-14B7-1-1 (1 ml of ascites fluid),
was immobilized using an ImmunoPure™ Protein G IgG
Orientation Kit (Pierce) as instructed by the manufacturer.
This antibody recognizes the 63 kDa receptor binding
region (C-terminus) of the PA molecule [18]. PA17 kDa N-
terminal fragment (LIST Biological Laboratories, Inc.; sold
as PA20), 500 μl containing 250 μg of protein, was diluted
with an equal volume of PBS (pH 7.3, Sigma, St. Louis,
MO). The resulting 1 ml was combined with 1 ml of
immobilized antibody and incubated at room tempera-
ture on a rotator for 2 hours. The suspension was then
centrifuged at 3000 × g for 5 minutes to recover PA17 in the
supernatant fraction, filtered through a 0.2 μm cellulose
acetate low protein binding filter (Corning, Lowell, MA)
and frozen in aliquots at -70°C. Proteins were analyzed by
SDS PAGE using 4–15% PhastGels (Amersham, Piscata-
way, NJ) and Western Blot as previously described [16].
Construction of a PA-Factor Xa recombinant strain and 
purification of PA 20 kDa fragment designated as rPA20
The amino-terminal domain of PA is cleaved at the con-
sensus R164–K165–K166–R167 sequence recognized by
furin-like proteases in-vitro [12] and by a plasma protease
in vivo [16]. This process results in the release of a 20-kDa
amino-terminal fragment (PA20) and the formation of 63-
kDa carboxy-terminal fragment heptamers [19]. Lethal
factor (LF) and/or edema factor (EF) then bind to the hep-
tamers and these toxic complexes are internalized via
receptor-mediated endocytosis into eukaryotic cells [20].
Limited digestion of PA with trypsin results in 63 kDa and
20 kDa fragments. These fragments were isolated and fully
characterized by Christensen et al. [21]. However, pro-
longed digestion with trypsin results in a trypsin resistant
17 kDa amino terminal fragment. Deletion of the consen-
sus R164–K165–K166–R167 sequence eliminates the
cleavage of PA by furin-like proteases and by trypsin [22].
In-vivo proteolysis of PA results in 63 kDa and 20 kDa frag-
ments [16]; therefore we wished to be able to produce an
identical and stable 20 kDa fragment in-vitro. In this study,BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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we performed mutagenesis of the trypsin cleavage site in
PA83 to make it sensitive to cleavage by Factor Xa protease
because there are no other Factor Xa sensitive sites on the
PA83 sequence. We constructed a PA mutant in which a
Factor Xa proteolytic recognition site (IEGR) was geneti-
cally engineered into PA [12]. The Factor Xa proteolytic
site was introduced into PA at the trypsin-sensitive site by
a 2-step mutagenesis procedure using a Muta-Gene
Phagemid InVitro Mutagenesis kit (BioRad, Hercules, CA).
A 2,044 bp HindIII/BamHI fragment encoding the car-
boxy-teminus of pag, including amino acid residues 164–
167 which comprise the trypsin-sensitive site, was
inserted into pBluescriptSK (Stratagene, La Jolla, CA.) and
designated pPAHB. Oligonucleotide XaFN (5'-GTACT-
TCGCTTTTCTATTGAGTTCGAAG-3') was used to convert
the wild-type pag gene fragment in pPAHB to an R164I/
K165E double mutant designated pPAHB(XaFN). Oligo-
nucleotide Xa2FN1  (5'-GTACTTCGCCCTTCTATTGAGT-
TCGAAG-3') was used to convert the pag double mutant
in pPAHB(XaFN) to K166G to complete the creation of
the Factor Xa site and was designated pPAHB(Xa2FN1). A
670 bp PstI/HindIII fragment from pPAHB(Xa2FN1) con-
taining the Factor Xa site codons was ligated into pYS5
similarly digested with PstI/HindIII to remove the wild
type 670 bp fragment and the resulting plasmid was des-
ignated pYS1Xa2FN1 [22]. pYS1Xa2FN1 was transformed
into Bacillus subtilis WB600 for expression of the PA/Factor
Xa mutant [23]. PA/Factor Xa was purified from WB600
PYS1Xa2FN1 as previously described for rPA [24].
Endotoxin assay
We carried out endotoxin assays on the LIST PA20 and the
Factor Xa PA20 that we prepared. Both preparations had
less than 0.1 EU/ml as determined by using the Limulus
Amebocyte Lysate (LAL) QCL-1000 assay kit (Cambrex
Bio Science Walkersville, MD)
Exposure of monocytes and lymphocytes to rPA20
Leukopheresis units were obtained from volunteer donors
using the procedures outlined in our approved human use
protocol, reviewed by the established Institutional Review
Board at WRAIR. The written informed consent document
was provided to the volunteers in advance of the proce-
dure.
We obtained PBMC (4 different individuals over a period
of ~6 months, collected from ~8–10 AM to minimize var-
iability) from healthy human male volunteers who had
been screened to be HIV and Hepatitis B negative and
were from 19–61 years of age.
rPA20 was added to newly plated cells in flasks for the time
period specified. Cells incubated in the absence and pres-
ence of rPA20 were collected by centrifugation at the spec-
ified exposure time.
Exposure of monocytes and lymphocytes to the anthrax 
spores
Spores were prepared from B. anthracis Ames strain
(pXO1+, pXO2+). Briefly, 5% sheep blood agar (SBA)
plates were inoculated with B. anthracis Ames spores and
incubated overnight at 35°C. Several isolated colonies
were transferred to a sterile screw capped tube containing
5 ml of sterile PBS. NSM Petri plates (New sporulation
medium: per liter added Tryptone; 3 g, Yeast extract; 3 g,
Agar; 2 g, Lab Lemco agar; 23 g, and 1 ml of 1%
MnCl2·4H2O) were inoculated with 200 μl of the pre-
pared cell suspension. The plates were incubated for 48
hrs at 35°C and checked for sporulation progress by
microscopic examination. Continued incubation at room
temperature was performed until free refractive spores
constituted 90–99% of total suspension. Spores were then
harvested from plates using 5 ml of sterile water. Spores
were washed 4 times in sterile water and checked for
purity by plating 10 μl in triplicate onto 5% SBA plates
and incubating overnight @ 35°C. Enumerations of
spores were calculated via CFU/ml (determination of via-
ble spores) and also for actual spores/ml using Petroff
Hauser chamber.
ELISA immunoassays
An ELISA kit for TNF-α was used to determine TNF-α lev-
els in PBMC cells treated with rPA20 according to manufac-
turer's instructions (Quantikine R&D systems,
Minneapolis, MN). The amount of protein was quantified
using Ceres UV 900-Hdi plate reader (Bio-Tek Instru-
ments Inc., Winooski, VT).
Extraction of RNA
Total RNA was isolated from cells using the TRIzol™ rea-
gent (Invitrogen, Carlsbad, CA) according to the manufac-
turer's instructions. The RNA samples were treated with
DNase-1 to remove genomic DNA and were re-precipi-
tated with isopropanol. The quality of the RNA to be used
for microarray was characterized using a 2000 BioAna-
lyzer (Agilent, Santa Clara, CA) to verify the presence of
18 and 28S bands, to confirm the lack of degradation.
RNA quantity was determined using a Nanodrop spectro-
photometer.
cDNA microarrays
Preparation of Microarray Chip: Human cDNA microar-
rays were generated using sequence verified PCR elements
including the approximate 6900 well-characterized
human genes from The Easy to Spot Human UniGEM
V2.0 cDNA (Incyte Genomics, Inc). The PCR products
ranging from 500–700 base pairs were deposited in 3X
saline sodium citrate (SSC) at an average concentration of
165  μg/μl on CMT-GAPS II aminopropyl silane-coated
slides (Corning, Corning, NY) using a VersArray microar-
ryer (Bio-Rad, Inc). The arrays were post processed by UV-BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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cross linking at 1200 mjoules, baking for 4 hours at 80°C,
and then the positively charged amine groups on slide sur-
face were inactivated through reacting with succinic anhy-
dride/N-methyl-2-pyrrolidinone. Upon hybridization,
the quality of each microarray, i.e. the efficiency of reverse
transcription (RT) reactions, labeling competence etc. was
assessed.
Microarray hybridization and image processing
Microarray labeling was performed using Micromax Tyra-
mide Signal Amplification (TSA) Labeling and Detection
Kit (Perkin Elmer, Inc., MA). The slides were hybridized
for 16 h at 60°C. The GenePix Pro 4000b (Axon Instru-
ments, Inc., CA) optical scanner was used to scan the
hybridized slides and the raw intensity was recorded
through the Gene Pix 4000 software package (Axon
Instruments, Inc., CA). Intensity of the scanned images
was digitalized through Genepix 4.0 software.
Data analysis
Assessment of the overall integrity of the microarray
experiment:
Microarray images were visualized using Imagene v.6
(BioDiscovery, Inc., El Segundo, CA) and data were ana-
lyzed using GeneSpring V. 7.1 (Agilent, Santa Clara, CA)
and Partek Pro. V. 5.0 (Partek, St Louis, MI). Data cleans-
ing and normalization: Using ImaGene (BioDiscovery
Inc), background and foreground pixels of each spot were
segmented and the highest and lowest 2% of the probe
intensity was discarded. Local background correction was
applied to each individual spot. The genes that passed this
filter in all given experiments were selected for further
study.
Data cleansing and statistical analysis was carried out
using GeneSpring® 7.1 (Agilent Tech., CA). Local back-
ground was subtracted from individual spot intensity.
Genes that failed this 'background check' in any of the
experiments were eliminated from further analysis. Each
chip was next subjected to intra-chip normalization
(LOWESS). The genes that varied most between control
and treated sample sets were selected via t-test analysis.
The p-value cutoff was set at 0.05.
We used the reference design, where a reference RNA sam-
ple is co-hybridized with each sample on the slide. This
design allows us to normalize between slides for varia-
tions that can be due to hybridization, transcription and
labeling efficiencies (technical variations).
Apoptosis study using Hoechst 33258
PBMC were treated with rPA20 for 24 h. Cells were stained
with Hoechst 33258 dye for 30 min and examined by flu-
orescence microscopy. Cells having bright; fragmented
and condensed nuclei were identified as apoptotic cells.
The number of apoptotic cells was counted in 10 micro-
scopic fields (×40) in each case.
Caspase enzymatic assay
Caspase activity in PBMC cells exposed to LIST PA17 and
to rPA20 was studied using the EnzChek® Caspase-3 Assay
Kit #2 (Invitrogen, Carlsbad, CA). Cells were harvested
after 24 hrs of exposure to rPA20 and washed in PBS. Cells
were lysed and centrifuged. The Z-DEVD-R110 substrate
solution was added to each of the treated and control
samples. The mixture was incubated for 30 min and the
fluorescence was measured at excitation/emission ~496/
520 nm.
CD38 staining of PBMC cells
Peripheral blood mononuclear cells were incubated with
rPA20 for 16 hours. Cells were then washed twice with PBS
and labeled with allophycocyanin (APC)-conjugated
mouse anti-human CD38 monoclonal antibody (Becton
Dickinson Biosciences, Franklin Lakes, NJ), followed by
incubation on ice for 30 min in the dark. The cells were
then washed and resuspended at 2 × 106 cells/ml in cell
buffer (cell assay reagents, Agilent Technologies, Palo
Alto, CA). A cell assay LabChip (Agilent Technologies)
was primed with priming solution (Agilent Technolo-
gies), after which 10 μl of the cell suspension (20,000
cells) was added to one of six channels. A focusing dye was
applied to another chamber, which acted as a reference for
the optical detection system. The chip was then placed in
an Agilent Technologies Model 2100 bioanalyzer and flu-
orescence from the cells was measured. Fluorescent events
were plotted against the fluorescent intensity (frequency
histogram).
Results
Analysis of PA17 obtained from LIST Biologicals, Inc
Subsequent to portions of this investigation, it was noted
in other studies that the PA fragment obtained from LIST
Biologicals, Inc., appeared smaller on Western blots than
PA20 detected in blood of infected animals (Figure 1). As
can be seen in lane 1 the purported 20 kDa PA from LIST
was smaller than the PA20 from infected animals (lane 3).
To address this disparity in size, Dr. Harry Hines and his
staff in the Toxinology Division, USAMRIID, performed
electrospray mass spectrometry on the commercially
obtained PA17. It was determined that the size of the pro-
tein moiety was 17 kDa rather than 20 kDa. Upon this dis-
covery, an alternative source of PA20  was generated
through recombinant DNA methodology as described in
the following section.BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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Construction of a PA-Factor Xa recombinant strain and 
purification of PA 20 kDa fragment designated as rPA20
The two furin-like protease or trypsin cleavage sites in PA
result in a 20 kDa fragment that subsequently is reduced
to 17 kDa. In order to prevent that from occurring, the
sequence R164–R167 was changed from RKKR to IEGR as
described in materials and methods. Deletion of the con-
sensus R164–K165–K166–R167 sequence was shown pre-
viously to eliminate the cleavage of PA by furin-like
proteases and by trypsin [22]. The purified protein was
digested with Factor Xa protease (Figure 2). SDS PAGE
and N-terminal sequence analysis confirmed that the 63-
kDa and 20 kDa fragments produced were identical to the
fragments produced from wild type PA by limited trypsin
digestion (not shown).
Purification of the 20 kDa fragment from PA after 
insertion of the Factor Xa sensitive sequence
Purified 83 kDa rPA was treated for 30 min at 37°C with
bovine plasma Factor Xa (Pierce) resulting in PA 20 and
63 kDa fragments. LF was added and allowed to oligomer-
ize with the PA63 at room temperature for 15 minutes. The
mixture was applied to Superose 6 size exclusion column
(Amersham-Pharmacia) in PBS and resulted in 3 peaks.
The proteins in each peak were identified by SDS PAGE
and Western blot. The first peak contained PA63 and LF,
the second peak contained LF and the third peak con-
tained rPA20. The rPA20  peak was further purified by
Immunoaffinity to be certain that the rPA20 would not
contain any residual PA63 as follows.
The monoclonal antibody BA-PA2II-14B7-1-1 (1 ml of
ascites fluid) which recognizes the receptor binding
region (C-terminus) of the PA molecule was immobilized
using an ImmunoPure™ Protein G IgG Orientation Kit
(Pierce) as instructed by the manufacturer [18]. 200 μg of
rPA20 kDa (n-terminal PA fragment purified by the Super-
ose exclusion column above) was combined with 1 ml of
immobilized antibody and incubated at room tempera-
ture on a rotator for 2 hours. The suspension was then
centrifuged at 3000 × g for 5 minutes to recover the rPA20
containing supernatant fraction. The purified rPA20 was
SDS-PAGE Western blot of anthrax infected rabbit plasma  showing PA20 and PA63 just prior to death Figure 1
SDS-PAGE Western blot of anthrax infected rabbit 
plasma showing PA20 and PA63 just prior to death. 
Lanes 1 to 4 were stained with anti-PA20 specific MAb and 
lanes 5 to 8 stained with anti – PA63 specific MAb. Lanes 1 
(arrow points to PA17) and 5 were loaded with the LIST PA17 
at 5 mg/ml. Lanes 2 and 6 were left blank to minimize cross 
contamination. Lanes 3 (arrow points to PA20) and 7 (arrow 
points to PA63) were loaded with 1:20 dilution of plasma 
from Ames strain challenged rabbit #41 just prior to death. 
Lanes 4 (arrow points to PA83) and 8 (arrow points to PA83) 
were loaded with purified PA83 @ 10 mg/ml.
1234 5678 SDS-Page analysis of the 83 and the PA63 and PA20 fragments Figure 2
SDS-Page analysis of the 83 and the PA63 and PA20 
fragments. PA/Factor Xa was purified from WB600 
PYS1Xa2FN1 (Lane 1). The purified protein was digested 
with Factor Xa protease (Lane 2) resulting in PA63 and PA20 
fragments; Wild type control PA83 treated with Factor Xa 
protease did not result in PA fragments (Lane 3).BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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compared to the LIST PA17 by SDS PAGE using 4–15%
PhastGels (Amersham) (Figure 3).
Gene expression patterns of PBMC exposed to rPA20 in 
vitro
PBMC samples obtained from 4 healthy individuals were
incubated with 2 μg/ml of the rPA20 for 4 hrs. Microarray
experiments were carried out using custom made cDNA
chips. The RNA quality was characterized beforehand
using a BioAnalyzer 2000 (Agilent, CA). Upon hybridiza-
tion, the quality of each microarray, i.e. the efficiency of
reverse transcription (RT) reaction, labeling competence,
were assessed using RNA spikes (Invitrogen, CA). Inter-
chip and intra-chip data normalizations were computed,
as described in the Materials and Methods, using Gene-
Spring Software (Silicon Genetics, CA). One-way ANOVA
with a p-value < 0.05 was applied to identify genes differ-
entially regulated by rPA20. Figures 4a and 4b are cluster
views of gene expression profiles in PBMC cells obtained
from four donors and exposed to rPA20.
To confirm that the results observed in PBMC cells
exposed to rPA20 were effects specific to rPA20, we dena-
tured rPA20 by heating the peptide at 95°C for 10 min
before adding it to the cells. Equal amounts (2 μg/ml) of
the native and the denatured peptides were added to the
cells and global gene expression analyses were carried out
to compare the effect of native and denatured rPA20 on
PBMC cells (Figure 5a). We found minimal variation in
gene expression profiles in PBMC cell exposed to rPA20
when compared with the control untreated PBMC (Figure
5b).
We also studied the expression of TNF-α using ELISA in
PBMC cells exposed to the native and denatured rPA20 and
found no significant change in the expression of TNF-α in
cells exposed to heat denatured rPA20. However, an
increase in the expression of TNF-α was observed in cells
treated with the native rPA20 peptide (Figure 5b).
Study of the gene expression profiles in PBMC exposed to 
rPA20 compared to B. anthracis
The gene expression profiles of PBMC cells exposed to
rPA20 were compared with those obtained from PBMC
exposed to B. anthracis at the same time points. We found
that a significant number of genes were similarly regulated
in rPA20 exposed cells when compared to cells exposed to
the full pathogen (Figure 6).
Analysis of genes regulated in response to the rPA20
We applied ANOVA to identify the statistically significant
genes that were altered with a p-value < 0.05 within the
control and treated samples. Of the genes that were signif-
icantly up regulated by rPA20 in PBMC, we identified
genes involved in cell adhesion, cell apoptosis, signaling
and immune and inflammatory responses. Cytokine
related genes were also regulated by rPA20. TNF-α, IL-1B,
and IL-6 receptor were highly up regulated in PBMC
treated with rPA20 (Figure 7).
We used GeneCite software, a high throughput pathway
analysis tool developed by our group, to identify path-
ways regulated by PA17 in PBMC [25]. A dramatic finding
was that components of the cell adhesion pathway were
up regulated by rPA20 in PBMC (Figure 8).
Another pathway found to be regulated was the Fas path-
way. Figure 9 illustrates expression patterns of some of
these components in cells treated with rPA20.
Induction of apoptosis by rPA20
PBMC cells were stained with the DNA binding dye
Hoechst 33258 to determine the number of apoptotic
cells. When PBMC cells were incubated with rPA20 for 24
hours, the percentage of apoptotic cells was increased by
more than 5-fold with respect to control cells (Figure 10).
Similar effects were observed in cells incubated with the
PA17 peptide. We have also studied the effect of PA17 and
rPA20 on the caspase activity and found increased enzy-
matic activity of Caspase 3 in PBMC that were exposed to
PA17 and rPA20 (Figure 11).
Effect of rPA20 on CD38 cells
Microarray data analysis showed that CD38 transcription
level was significantly down regulated in PBMC treated
with rPA20. We carried out an antibody staining analysis
of CD38 using the cell chip assay on the Bioanalyzer 2100
and found a decrease in CD38-associated fluorescence
(Figure 12).
Western blot comparison of recombinant PA20 from the PA/ Factor Xa mutant (lanes 1–4) and the commercial PA17 (lanes  5–7) product at quantities varying from 1 to 5 μg of the puri- fied rPA20 Factor Xa and the LIST PA17 Figure 3
Western blot comparison of recombinant PA20 from 
the PA/Factor Xa mutant (lanes 1–4) and the com-
mercial PA17 (lanes 5–7) product at quantities vary-
ing from 1 to 5 μg of the purified rPA20 Factor Xa and 
the LIST PA17. Purified 83 kDa PA/Factor Xa was treated 
for 30 min at 37°C with bovine plasma Factor Xa resulting in 
PA20 and PA63 kDa fragments. LF was added and allowed to 
oligomerize with the PA63 at room temperature for 15 min-
utes. The mixture was applied to Superose 6 size exclusion 
column (Amersham-Pharmacia) in PBS and resulted in 3 
peaks. The rPA20 was further purified by Immuno-affinity.BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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Discussion and conclusion
It is widely accepted that B. anthracis toxins contribute to
anthrax pathogenesis and to date, only the combination
of the PA63 fragment in association with LF or EF have
been described. PA is secreted by the bacterium as an 83
kDa protein which is rapidly cleaved in sera to PA63 and a
remaining 20 kDa fragment. PA63 has been shown to
form a heptamer that binds LF and forms a cellular pore
via receptor mediated endocytosis to facilitate the entry of
LF or EF into the host target cells. We have detected PA20
in the blood of infected animals, and to date no activity
has been described for this PA fragment. In addition,
PA83 has not been detected in the blood of B. anthracis
infected animals. We have previously reported that PA83
is cleaved by a calcium dependent plasma protease to
PA63 which forms oligomeric complexes with other PA63
and LF (and possibly EF), to result in the respective
anthrax toxins [17].
Although the 20 kDa fragment of PA is commercially
available (LIST Biologicals), our recent studies showed
that the procedure used resulted in a trypsin resistant 17
rather than a 20 kDa fragment (mass spectroscopy analy-
sis). In contrast, in vivo, the fragment produced is 20 kDa.
Although we used the rPA20 for the studies reported here,
we showed that the PA17 has similar activities to the rPA20
on PBMC. To understand the role that PA20 plays in the
pathogenesis of B. anthracis, we carried out a global
genomic analysis of the effect of rPA20 on PBMC in vitro.
Some of the genes found to be regulated by rPA20 are
Pseudo color cluster view of up regulated (a) and down regulated genes (b) in PBMC in response to 2 μg/ml the rPA20 Figure 4
Pseudo color cluster view of up regulated (a) and down regulated genes (b) in PBMC in response to 2 μg/ml 
the rPA20. Cells were obtained from 4 different donors and were treated with the rPA20. RNA was isolated and hybridized 
on the cDNA microarray slides as detailed in Materials and Methods. Images were analyzed using GenePix 4.0 and data were 
analyzed using GeneSpring 7.0. The expression data for these genes are listed in table 1. These genes were identified, using 
ANOVA t-test with a p < 0.05, to be highly significantly regulated when compared to the control untreated cells.
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Table 1: Gene identified to be highly significantly regulated by B. anthracis
Gene/protein Donor 1 Donor 2 Donor 3 Donor 4
6-pyruvoyltetrahydropterin synthase 2.265 0.4394 2.262 2.789
acid phosphatase 1, soluble 1.845 2.053 0.8392 3.292
actin, beta -1.667 -2.469 -1.813 -0.7812
adenylate kinase 1 0.1362 0.4168 0.1217 0.406
alcohol dehydrogenase 1C (class I), gamma polypeptide -0.4945 -1.479 -1.452 -0.522
associated molecule with the SH3 domain of STAM (AMSH) like pro -1.286 -0.7072 -1.122 -0.319
AT rich interactive domain 5A (MRF1-like) -1.117 -1.173 -0.608 -0.7124
ATPase, aminophospholipid transporter (APLT), Class I, type 8A, m -0.867 -0.9902 -1.217 -1.002
ATPase, Ca++ transporting, plasma membrane 2 -1.185 -0.8227 -1.454 -1.233
ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d isoform 1 -1.254 -0.7821 -0.7238 -0.1514
ATPase, Na+/K+ transporting, alpha 3 polypeptide -0.5454 -1.172 -1.408 -0.5249
ATP-binding cassette, sub-family A (ABC1), member 3 -0.7075 -1.336 -0.9859 -0.3627
beta-transducin repeat containing -1.301 -1.458 -1.57 -0.5347
bromodomain and PHD finger containing, 3 -0.6459 -0.2634 -1.069 -0.3741
C1q and tumor necrosis factor related protein 1 1.072 1.119 0.9826 0.543
calsyntenin 3 -0.9132 -0.3774 -1.219 -0.3527
calumenin 0.8976 1.009 0.984 1.217
carbonic anhydrase X 1.494 1.533 1.664 0.2302
carcinoembryonic antigen-related cell adhesion molecule 7 0.5028 0.263 0.2265 0.2129
cathepsin D (lysosomal aspartyl protease) -0.4152 -0.3937 -1.185 -0.9571
CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1.8 1.456 2.398 2.843
CDNA FLJ45814 fis, clone NT2RP7018126 -0.7894 -1.97 -1.454 -0.923
centrin, EF-hand protein, 2 -0.8196 -2.365 -2.736 -1.134
chemokine (C-C motif) receptor 6 -0.4528 -0.2879 -0.6378 -0.2152
Clone IMAGE:4838790, mRNA -0.485 -0.9604 -0.515 -0.2199
cofactor required for Sp1 transcriptional activation, subunit 9, 33 kDa -0.8153 -0.4039 -1.577 -0.6495
complement component 3a receptor 1 -0.7288 -1.094 -1.152 -0.2907
dehydrogenase/reductase (SDR family) member 6 2.449 0.2412 2.836 2.234
DKFZP434P1750 protein -0.9027 -1.021 -0.6581 -0.8601
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 -0.7681 -1.55 -0.7539 -0.2911
ecotropic viral integration site 2B 0.7891 1.913 1.367 1.481
ELYS transcription factor-like protein TMBS62 0.7329 1.34 1.167 0.4772
endothelin receptor type B -0.7971 -0.6776 -1.425 -0.9299
ERO1-like (S. cerevisiae) -0.4751 -1.573 -2.013 -1.192
EST365748 MAGE resequences, MAGC Homo sapiens cDNA, mR -0.3974 -0.9129 -0.9105 -0.3948
eukaryotic translation initiation factor 4E binding protein 1 -0.6047 -1.043 -1.089 -1.082
family with sequence similarity 20, member A -0.26 -0.5113 -1.164 -1.137
F-box and leucine-rich repeat protein 7 2.838 1.484 1.225 3.888
fibronectin 1 -0.5673 -0.5845 -1.167 -1.708
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously 0.7983 1.141 0.7866 0.9328B
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FLJ20793 protein -0.9689 -0.9124 -1.154 -0.2331
formin-like 1 -0.8158 -1.599 -0.7554 -0.7411
GA binding protein transcription factor, alpha subunit 60 kDa -0.7418 -0.5199 -0.7053 -1.07
galactokinase 1 -0.1951 -0.4303 -0.27 -0.6901
gap junction protein, beta 5 (connexin 31.1) 1.095 1.524 0.9336 0.2265
GLE1 RNA export mediator-like (yeast) -0.8643 -0.341 -0.2584 -0.6748
glucosaminyl (N-acetyl) transferase 2, I-branching enzyme 2.377 1.534 2.844 1.225
GNAS complex locus -0.6085 -1.294 -1.715 -1.55
GRO3 oncogene -0.3814 -1.003 -0.9765 -0.7961
growth factor independent 1 1.282 0.2066 0.669 0.7891
growth hormone receptor -0.3103 -1.458 -0.8417 -1.296
H. sapiens ARS gene, component B. 0.3962 1.059 1.186 0.6116
heat shock 27 kDa protein 2 -0.6707 -0.7274 -2.224 -1.424
hemoglobin, zeta -0.4909 -0.8871 -0.4189 -0.149
high-mobility group 20A 1.768 2.038 0.7883 0.5271
Homo sapiens IGHG3 gene for immunoglobulin heavy chain gamma 1.585 1.946 1.511 1.761
Homo sapiens, clone IMAGE:3954961, mRNA, -1.437 -1.642 -0.8906 -1.996
HSPC135 protein 1.058 1.879 0.8552 0.5993
Human DNA sequence from clone XX-D88L2 on chromosome 1q32 -0.9986 -0.4828 -0.7607 -0.2225
hydroxysteroid (17-beta) dehydrogenase 2 -0.6315 -0.6454 -1.138 -0.4903
hypothetical LOC387763 1.165 0.827 0.3265 1.563
hypothetical protein FLJ10925 -1.163 -0.301 -1.229 -1.046
hypothetical protein FLJ12649 -1.138 -1.602 -1.002 -0.6636
hypothetical protein FLJ31842 -0.7517 -0.2782 -0.436 -0.1725
hypothetical protein IMPACT 0.7924 2.146 1.185 0.512
hypothetical protein LOC51321 -1.431 -0.7981 -0.5971 -0.5105
hypothetical protein MGC2655 3.033 1.669 0.7908 1.584
integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associate -1.358 -1.034 -0.7394 -0.4935
interleukin 6 (interferon, beta 2) -0.9922 -2.6 -1.892 -1.956
kallikrein 10 -0.7654 -0.3185 -1.353 -0.901
keratin, cuticle, ultrahigh sulphur 1 -1.208 -1.486 -1.002 -0.6479
KIAA0195 gene product -0.654 -2.765 -1.988 -1.192
KIAA0196 gene product -1.305 -1.098 -0.8417 -0.8635
KIAA0528 gene product 4.307 2.866 2.187 0.6229
KIAA0759 -0.8301 -0.759 -0.9988 -0.5301
KIAA1458 protein -1.232 -1.82 -0.9504 -0.4043
KIAA1539 -1.079 -1.772 -1.397 -0.9942
kinesin family member 4A -1.135 -1.455 -0.8039 -0.2817
kinetochore associated 2 -0.4972 -1.001 -1.011 -0.7954
kruppel-like zinc finger protein; Homo sapiens promyelocytic leukem -1.251 -0.9379 -1.973 -1.031
kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) -0.5685 -1.132 -1.798 -0.8039
LOC388610 (LOC388610), mRNA 2.319 0.3752 1.057 2.013
male sterility domain containing 1 -0.6454 -0.5462 -1.525 -1.041
Table 1: Gene identified to be highly significantly regulated by B. anthracis (Continued)B
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matrix metalloproteinase 16 (membrane-inserted) -1.777 -2.344 -1.65 -0.6869
mesothelin 1.045 1.22 1.54 0.1712
methylthioadenosine phosphorylase -1.51 -0.4183 -1.556 -1.119
mitochondrial ribosomal protein L44 1.706 1.743 0.4926 0.544
molybdenum cofactor synthesis 3 0.779 1.529 0.7891 0.2762
MRNA; cDNA DKFZp686H1039 (from clone DKFZp686H1039) 1.206 0.519 0.9084 1.165
mucin 5, subtype B, tracheobronchial -0.5146 -0.1101 -0.5376 -0.7425
Notch homolog 4 (Drosophila) 0.9252 1.024 0.1454 0.6285
nuclear receptor subfamily 1, group H, member 2 -0.3397 -1.337 -0.9731 -0.5515
paired box gene 3 (Waardenburg syndrome -0.6751 -0.4723 -0.6409 -0.6302
paraneoplastic antigen MA1 -0.67 -1.225 -0.48 -0.2581
PDZ and LIM domain 1 (elfin) 1.041 1.555 0.6517 1.342
peripheral myelin protein 22 -0.4552 -1.767 -1.706 -1.176
PFTAIRE protein kinase 1 -0.5164 -2 -2.035 -1.931
phosphatidylinositol glycan, class Q 1.067 1.114 1.141 0.3068
phytanoyl-CoA hydroxylase interacting protein -1.698 -0.07415 -1.755 -1.699
PlSC domain containing hypothetical protein -1.719 -0.4816 -1.777 -1.5
polymerase (RNA) III (DNA directed) polypeptide G (32 kD) 0.5734 1.622 3.274 3.359
POM (POM121 homolog, rat) and ZP3 fusion -0.647 -0.319 -0.7233 -0.117
potassium inwardly-rectifying channel, subfamily J, member 15 -0.9743 -2.059 -1.175 -0.5925
potassium large conductance calcium-activated channel, subfamily 2.751 1.112 0.5753 1.485
presenilin 2 (Alzheimer disease 4) -0.5609 -1.55 -0.9509 -0.4208
proline-serine-threonine phosphatase interacting protein 1 -0.2379 -0.5739 -0.8672 -0.4775
ProSAPiP2 protein -0.6497 -0.1215 -0.5855 -0.3364
protocadherin 11 Y-linked 1.474 1.825 1.35 0.5331
putative nucleic acid binding protein RY-1 -1.409 -1.09 -0.5389 -0.4293
putative protein similar to nessy (Drosophila) -0.7926 -0.8206 -0.5677 -0.7377
pyroglutamyl-peptidase I -0.1691 -0.7233 -0.8544 -0.5551
qp73h10.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clo -1.024 -1.686 -1.235 -0.9119
RAB30, member RAS oncogene family -1.838 -2.618 -0.917 -0.7415
RAB9B, member RAS oncogene family 0.2029 0.4147 0.4782 0.3173
RA-regulated nuclear matrix-associated protein -0.9885 -0.276 -0.4191 -0.4208
ras homolog gene family, member C 0.3334 0.346 0.2774 0.5479
REST corepressor 1 -0.2084 -1.375 -2.173 -1.47
retinitis pigmentosa 2 (X-linked recessive) 2.301 1.546 1.339 3.789
retinoblastoma-associated protein 140 -0.3049 -1.424 -1.341 -1.09
retinol binding protein 4, plasma -0.6962 -1.256 -2.234 -1.568
ribosomal protein L23 -1.188 -1.077 -1.345 -0.9045
ribosomal protein S20 -2.379 -2.005 -0.4064 -1.469
RNA (guanine-7-) methyltransferase -0.9669 -0.8633 -1.674 -0.3241
RWD domain containing 2 0.9411 1.362 2.293 2.374
SAM and SH3 domain containing 1 -0.9048 -1.158 -0.9225 -1.106
secretin receptor -0.3857 -2.202 -1.223 -1.245
Table 1: Gene identified to be highly significantly regulated by B. anthracis (Continued)B
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semenogelin II -0.9479 -0.872 -0.5137 -0.1655
SET translocation (myeloid leukemia-associated) -1.673 -0.5829 -1.633 -0.8802
sideroflexin 1 -0.4931 -0.7209 -0.8337 -0.8135
similar to human GTPase-activating protein -2.076 -1.635 -1.364 -0.8021
Similar to Lysophospholipase -0.9395 -1.975 -0.6778 -0.7481
small nuclear RNA activating complex, polypeptide 5, 19 kDa -1.124 -1.438 -0.372 -0.4988
snail homolog 1 (Drosophila) 1.386 2.22 0.6079 0.8456
solute carrier family 16 (monocarboxylic acid transporters), member -0.8285 -0.8079 -1.113 -0.09096
solute carrier family 34 (sodium phosphate), member 1 -0.2497 -0.9574 -0.6233 -0.55
solute carrier family 4, sodium bicarbonate cotransporter, member 7 1.666 2.241 0.4895 0.9819
somatostatin receptor 2 3.287 1.207 2.095 2.374
sorting nexin 15 -0.5503 -0.7774 -0.4106 -0.3535
SP110 nuclear body protein -0.699 -1.42 -1.406 -0.4606
START domain containing 3 -1.17 -2.012 -1.621 -0.4317
suppressor of var1, 3-like 1 (S. cerevisiae) -1.02 -0.8975 -0.4765 -0.2837
synovial sarcoma, X breakpoint 2 interacting protein 0.9957 1.435 0.8189 0.3763
TAF10 RNA polymerase II, TATA box binding protein (TBP)-associa 1.408 0.8041 1.358 0.5028
TAP binding protein (tapasin) 2.518 1.909 0.3718 1.161
thymus high mobility group box protein TOX 1.165 1.726 1.373 0.3885
toll-like receptor 3 -0.8173 -1.102 -1.35 -0.3895
TRAF and TNF receptor associated protein -1.192 -1.042 -0.7728 -0.1867
Transcribed sequence with strong similarity to protein ref:NP_05761 -1.382 -2.008 -0.7379 -0.4367
Transcribed sequence with weak similarity to protein ref:NP_06031 0.8875 1.208 0.9568 0.2339
Transcribed sequence with weak similarity to protein sp:P39193 (H. -1.096 -1.454 -1.585 -0.1049
Transcribed sequences 0.5241 0.8148 0.8891 1.009
Transcribed sequences -3.77 -2.45 -1.731 -0.6047
tribbles homolog 3 (Drosophila) -0.4489 -1.411 -1.424 -0.4251
troponin I, skeletal, slow -0.2777 -0.7372 -1.637 -1.618
tuberous sclerosis 2 0.7672 1.119 0.3896 1.254
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation -1.402 -1.306 -1.059 -0.2737
upstream regulatory element binding protein 1 -1.067 -1.853 -0.8107 -0.3799
vacuolar protein sorting 33B (yeast) 1.124 0.6897 1.236 1.376
WD and tetratricopeptide repeats 1 -1.529 -0.1551 -1.397 -0.9977
x 006 protein 1.105 1.55 3.65 2.442
X-ray repair complementing defective repair in Chinese hamster cell 0.9716 1.156 0.3796 0.6554
zinc finger and BTB domain containing 26 2.651 1.075 0.7553 1.785
zinc finger protein 23 (KOX 16) 2.372 2.401 0.8906 1.1
zinc finger, DHHC domain containing 18 -0.189 -0.3015 -0.6595 -0.228
zp19d06.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clo 1.479 0.8278 0.384 0.7579
Table 1: Gene identified to be highly significantly regulated by B. anthracis (Continued)BMC Infectious Diseases 2008, 8:124 http://www.biomedcentral.com/1471-2334/8/124
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related to apoptosis and cell growth. In addition, several
cytokine related genes were up regulated by rPA20. This
observation is consistent with the reported effect of B.
anthracisin vitro and  in vivo [26]. A recent publication
using modeling approaches identified a 14 kDa sequence
(14–150) as a critically conserved domain in bacterial tox-
ins, adhesins other crucial molecules for biological activ-
ity [27]. It should be noted that this study was a survey of
sequences using bioinformatics and modeling and did
not utilize an actual fragment from PA.
Another interesting observation is the effect of rPA20 on
the expression of CD38 that was significantly decreased
by rPA20. CD38 is a type II integral membrane receptor
and adhesion molecule [28] and serves as a cytotoxic trig-
gering molecule on natural killer cells [29].
Components of the Fas pathway were up regulated in
PBMC treated with rPA20. We have also found that rPA20
increased the caspase-3 activity in PBMC cells. Thus we
expected that rPA20 may induce apoptosis in these cells.
The accepted model of PA63/LF complex and the deleteri-
ous effects attributed to this complex have not taken into
consideration any possible effects of the rPA20 which is
released when the complex is formed. Here we propose
that rPA20 may be responsible for some of the effects pre-
viously ascribed to PA63/LF on host cells. A recent publica-
A. Cluster view of gene expression profiles in PBMC exposed to 2 μg/ml native and denatured rPA20 compared to the control  untreated Figure 5
A. Cluster view of gene expression profiles in PBMC exposed to 2 μg/ml native and denatured rPA20 compared 
to the control untreated. The peptide was heat denatured at 95°C for 15 min. prior to adding it to the cells. Equal amounts 
of the native and denatured peptides were added to the cells and incubated for 4 hrs. Data were normalized to the control 
untreated cells. B. Expression levels of TNF-α in PBMC cells exposed to the native and denatured rPA20. Cells were incubated 
with 2 μg/ml of the two peptides separately and the expression of TNF-α was examined using ELISA.
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Cluster analysis of the gene expression profiles of PBMC  cells exposed to rPA20 compared with those obtained from  PBMC exposed to B. anthracis for 4 hrs Figure 6
Cluster analysis of the gene expression profiles of 
PBMC cells exposed to rPA20 compared with those 
obtained from PBMC exposed to B. anthracis for 4 
hrs. RNA samples were isolated and hybridized on the 
cDNA micorarray slides as detailed in materials and meth-
ods. Images were analyzed using GenePix 4.0 and data were 
analyzed using GeneSpring 7.0 to identify up regulated (6a) 
and down regulated genes (6b).
A. B.
Expression profiles of IL-1β, IL-6R and TNF-α in response to  rPA20 in PBMC Figure 7
Expression profiles of IL-1β, IL-6R and TNF-α in 
response to rPA20 in PBMC. Cells were incubated with 
the rPA20 for 4 hrs. RNA samples were isolated and hybrid-
ized on the cDNA micorarray slides as detailed in materials 
and methods. Images were analyzed using GenePix 4.0 and 
data were analyzed using GeneSpring 7.0.
0
0.5
1
1.5
2
2.5
3
3.5
4
IL-1B IL-6R TNF-a
F
o
l
d
 
C
h
a
n
g
e
Control
rPA20
Expression profile of genes related to the cell adhesion path- way that were up regulated by rPA20 in PBMC Figure 8
Expression profile of genes related to the cell adhe-
sion pathway that were up regulated by rPA20 in 
PBMC. Cells were incubated with the rPA20 for 4 hrs. RNA 
samples were isolated and hybridized on the cDNA micorar-
ray slides as detailed in materials and methods. Images were 
analyzed using GenePix 4.0 and data were analyzed using 
GeneSpring 7.0. Data were then analyzed using GeneCite to 
identify pathways regulated by the rPA20. These genes are 
platelet/endothelial cell adhesion molecule 1 (PECAM1), 
breast cancer anti-estrogen resistance (BCAR), capping pro-
tein (actin filament) muscle Z-line, alpha 1 (F-actin), actinin, 
alpha 2, catenin alpha and PTK2 protein tyrosine kinase 2 
(PTK2).
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Expression profile of genes related to the Fas pathway that  were regulated by rPA20 in PBMC Figure 9
Expression profile of genes related to the Fas path-
way that were regulated by rPA20 in PBMC. Cells were 
incubated with the rPA20 for 4 hrs. RNA samples were iso-
lated and hybridized on the cDNA micorarray slides as 
detailed in materials and methods. Images were analyzed 
using GenePix 4.0 and data were analyzed using GeneSpring 
7.0. Data were then analyzed using GeneCite to identify 
pathways regulated by the rPA20. These genes are caspase 
10, Fas (TNFRSF6)-associated via death domain (FADD), p21 
(CDKN1A)-activated kinase 2 (PAK2), mitogen-activated 
protein kinase kinase kinase 7 (MAPKKK7), Rho GDP disso-
ciation inhibitor (GDI) alpha (D4-GDI), ADP-ribosyltrans-
ferase (NAD+; poly (ADP-ribose) polymerase), 
retinoblastoma 1 and tumor necrosis factor receptor super-
family, member 6 (FAS).
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Induction of apoptosis in PBMC with rPA20 Figure 10
Induction of apoptosis in PBMC with rPA20. Cells were incubated with the rPA20 for 24 hours. Cells were then stained 
with HOECHST 33258 dye for 15 minutes. Cells with bright, fragmented, condensed nuclei were identified as apoptotic cells. 
This experiment was conducted at least 4 times (representative field shown here).
Control PA-17
LIST PA17 and rPA20 induce Caspase 3 enzymatic activity in PBMC Figure 11
LIST PA17 and rPA20 induce Caspase 3 enzymatic activity in PBMC. Cells were exposed to LIST PA17 and to rPA20 
separately and harvested at indicated time points. Cells were lysed and centrifuged. The mixture was incubated for 30 min and 
the fluorescence was measured using excitation/emission ~496/520 nm.
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tion described the association of rPA20 with LF [30]; it is
therefore possible that PA20  has additional functions
which may contribute to pathogenesis and should be con-
sidered.
Conclusion
The 20 kDa component of the protective antigen may play
a role in the pathogenesis of Bacillus anthracis and should
be studied in more details.
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(APC)-conjugated mouse anti-human CD38 monoclonal anti-
body. Samples were loaded onto a cell chip which deter-
mined cell associated fluorescence. Data are expressed as 
percent of CD38 fluorescent cell compared to total cell 
number (+/- standard deviation) and represent the results of 
three separate experiments performed in triplicate.
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